PYXS Pyxis Oncology, Inc.

CIK 0001782223 27 ready 8-Ks latest May 14, 2026, 7:36 AM ET RSS · JSON

Activity: NORMAL 1 filings / 30d vs 1 baseline Risk accumulating: repeated leadership change (2)

Ready 8-Ks 27

Latest filing May 14, 2026, 7:36 AM ET

Top materiality 0.85

Event mix earnings ×9 · other_material ×8 · leadership ×5

Sentiment 8 pos · 0 neg · 19 neu

Latest earnings ▼ miss 2025-Q3

Executive change recent →

Recent 8-K filings for PYXS

Highest-materiality recent filing

Pyxis Oncology MICVO Phase 1 shows 46% ORR monotherapy, 71% ORR with Keytruda in HNSCC

December 18, 2025, 6:59 PM ET other material materiality 0.85 positive item 7.01 item 8.01 item 9.01

MICVO monotherapy at 5.4 mg/kg: 46% confirmed ORR (6/13), 92% DCR in 2L+ R/M HNSCC; no Grade 4/5 TRAEs.
MICVO + Keytruda (3.6/4.4 mg/kg): 71% confirmed ORR (5/7), 100% DCR in 1L/2L+ HNSCC; no TRAE discontinuations.

Read filing →

May 14, 2026, 7:36 AM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Pyxis Oncology Q1 2026 net loss $23.3M; MICVO data on track for mid-2026

Net loss $23.3M ($0.37/share) vs $21.2M ($0.35/share) YoY; R&D expenses rose to $20.0M from $17.0M.
March 23, 2026, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 7.01 item 9.01

Pyxis Oncology completes MICVO enrollment, reports FY2025 net loss of $79.6M, names Interim CEO

Completed target enrollment (n~40) for MICVO Phase 1 monotherapy dose expansion in 2L+ R/M HNSCC in Q1 2026.
February 6, 2026, 6:59 PM ET leadership materiality 0.65 neutral item 5.02 item 7.01 item 9.01

Pyxis Oncology CEO Dr. Lara Sullivan steps down; board member Tom Civik appointed interim CEO

Effective February 2, 2026, Dr. Lara Sullivan stepped down as President, CEO, and CMO of Pyxis Oncology.
December 18, 2025, 6:59 PM ET other material materiality 0.85 positive item 7.01 item 8.01 item 9.01

Pyxis Oncology MICVO Phase 1 shows 46% ORR monotherapy, 71% ORR with Keytruda in HNSCC

MICVO monotherapy at 5.4 mg/kg: 46% confirmed ORR (6/13), 92% DCR in 2L+ R/M HNSCC; no Grade 4/5 TRAEs.
August 14, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Pyxis Oncology Q2 2025 net loss $18.4M, cash $90.4M; MICVO data milestones ahead

Revenue of $2.8M from milestone payment for suvemcitug approval in China, compared to $0 in Q2 2024.
May 15, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 7.01 item 9.01

Pyxis Oncology Q1 net loss $21.2M ($0.35); cash $106.9M; MICVO data on track for H2 2025

Net loss $21.2M ($0.35/share) vs $3.3M ($0.06) in Q1 2024; prior year included $16.1M Novartis settlement revenue.
March 18, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 5.02 item 7.01 item 9.01 ◈ executive_change ×2

Pyxis Oncology reports FY2024 net loss $77.3M; MICVO 50% ORR in HNSCC; workforce cut 20%

Full year 2024 net loss $77.3M ($1.32 per share) vs $73.8M ($1.85) in 2023; cash $128.4M into 2H26.
February 26, 2025, 6:59 PM ET regulatory materiality 0.65 positive item 8.01 item 9.01

Pyxis Oncology receives FDA Fast Track for PYX-201 in head and neck cancer

FDA granted Fast Track Designation to PYX-201 for recurrent/metastatic HNSCC after prior chemo and anti-PD-(L)1.
December 19, 2024, 6:59 PM ET other material materiality 0.75 positive item 8.01 item 9.01

Pyxis Oncology prioritizes PYX-201 after 50% ORR in HNSCC; suspends PYX-106

Confirmed 50% ORR and 100% DCR in 6 heavily pretreated HNSCC patients in Phase 1 of PYX-201.
November 20, 2024, 6:59 PM ET other material materiality 0.85 positive item 7.01 item 9.01

PYX-201 achieves 50% ORR in HNSCC; Merck collaboration for KEYTRUDA combo

PYX-201 achieved 50% confirmed ORR by RECIST 1.1 (1 CR, 2 PR) and 100% DCR in 6 heavily pretreated HNSCC patients.
November 12, 2024, 6:59 PM ET other material materiality 0.60 neutral item 2.02 item 9.01

Pyxis Oncology reports Q3 2024 net loss of $21.2M; cash runway into 2H 2026

Cash and equivalents of $146.3M as of Sept 30, 2024; expected to fund operations into 2H 2026.
August 14, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 9.01

Pyxis Oncology Q2 net loss $17.3M; cash $157.2M funds into 2H 2026

Net loss $17.3M ($0.29/shr) vs $15.9M ($0.41/shr) in Q2 2023; R&D spend $13.9M.
May 14, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02 item 9.01 ◈ Earnings Releases

Pyxis Oncology Q1 net loss narrows to $3.3M; PYX-201 data on track for fall 2024

Revenue of $16.1M from Novartis royalty settlement; net loss $3.3M ($0.06/sh) vs $19.2M ($0.54/sh) YoY.
March 21, 2024, 7:59 PM ET earnings materiality 0.65 neutral item 2.02 item 7.01 item 9.01 ◈ Earnings Releases

Pyxis Oncology reports FY2023 net loss of $73.8M, advances PYX-201 and PYX-106 trials

Net loss of $73.8M ($1.85/share) vs $120.7M ($3.65/share) in FY2022; R&D expenses fell to $49.6M from $86.1M.

Executive changes

Departed

Lara Sullivan

Director

PYXS · Pyxis Oncology, Inc.

Effective: 2026-04-29
Filed: April 30, 2026, 7:59 PM ET

Also on the Effective Date, Dr. Sullivan resigned from the Board of Directors of the Company.

Departed

Lara Sullivan

Chief Executive Officer

PYXS · Pyxis Oncology, Inc.

Effective: 2026-04-29
Filed: April 30, 2026, 7:59 PM ET

On April 29, 2026 (the “Effective Date”), the Separation Agreement between the Company and Dr. Sullivan became binding and effective, addressing Dr. Sullivan’s separation from the Company.

Role change

Lara S. Sullivan

Chief Medical Officer

PYXS · Pyxis Oncology, Inc.

Effective: 2025-03-18
Filed: March 18, 2025, 7:59 PM ET

Lara S. Sullivan, M.D., President and Chief Executive Officer will assume the role of Chief Medical Officer along with her current role as President and Chief Executive Officer.

Departed

Ken Kobayashi

Chief Medical Officer

PYXS · Pyxis Oncology, Inc.

Effective: 2025-03-18
Successor: Lara S. Sullivan
Filed: March 18, 2025, 7:59 PM ET

On March 18, 2025, the Company announced that Ken Kobayashi, M.D., F.A.C.P, is stepping down from his position as the Company's Chief Medical Officer.

Appointed

Michael A. Metzger

Director

PYXS · Pyxis Oncology, Inc.

Effective: 2024-06-10
Filed: June 10, 2024, 7:59 PM ET

On June 10, 2024, Pyxis Oncology, Inc. (the “Company”), appointed Michael A. Metzger, to its Board of Directors (the “Board”).

Appointed

Santhosh Palani, Ph.D., CFA

Director

PYXS · Pyxis Oncology, Inc.

Effective: 2024-03-12
Filed: March 13, 2024, 7:59 PM ET

On March 12, 2024, Pyxis Oncology, Inc. (the “Company”), appointed Santhosh Palani, Ph.D., CFA ® , to its Board of Directors (the “Board”).

Earnings & guidance

2025-Q3 EPS reported -$0.99 vs consensus -$0.35 ▼ miss (-186.7%) filing →

Materiality & sentiment trend

Max materiality 0.85 · Median 0.60 · Most common event earnings

8 positive 0 negative 19 neutral

source · PYXS on sec.gov